Richard Pazdur

TL;DR: Combining TS inhibitors with other agents that affect TS, interfere with TS gene and mRNA regulation, or inhibit salvage mechanisms of thymidylate depletion may potentially enable greater clinical utility of this class of compounds.

TL;DR: Pemetrexed in combination with cisplatin was approved by the FDA on February 4, 2004 for the treatment of patients with MPM whose disease is either unresectable or who are otherwise not candidates for curative surgery.

TL;DR: Ibrutinib is a first-in-class Bruton's tyrosine kinase (BTK) inhibitor that received all four expedited programs of the FDA: Fast-Track designation, Breakthrough Therapy designation, Priority Review, and Accelerated Approval.

TL;DR: Key review findings that supported approval of atezolizumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma are summarized.

TL;DR: In patients treated with atezolizumab, the most common adverse reactions were fatigue, decreased appetite, dyspnea, cough, nausea, musculoskeletal pain, and constipation;The most common (≥2%) grade 3 to 4 adverse events were dysPnea, pneumonia, hypoxia, hyponatremia, fatigue, anemia, muscleskeletalPain, and arthralgia.